JANXHIGH SIGNALFINANCIAL10-K

JANX experienced severe cash burn with operating cash flow nearly doubling to -$82.2M while cash reserves plummeted 87.8% to just $52.3M, creating potential liquidity concerns.

The company's cash runway has been dramatically shortened as R&D expenses surged 84% while cash reserves fell to approximately 8 months of operating expenses at current burn rates. This deterioration suggests JANX will likely need additional financing within the next year to continue operations.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

JANX showed dramatic financial deterioration with operating cash flow worsening by 87.7% to -$82.2M driven by R&D expenses that nearly doubled to $125.9M, while cash reserves collapsed from $430.6M to just $52.3M. Net losses deepened by 64.7% to -$113.6M as current liabilities increased 43.2%, painting a picture of accelerated spending with severely diminished liquidity. The combination of doubled burn rate and depleted cash position signals an urgent need for capital raising to maintain operations beyond the current year.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+190.5%
$359K$1.0M

Capital expenditure jumped 190.5% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
-87.8%
$430.6M$52.3M

Cash declined 87.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-87.7%
-$43.8M-$82.2M

Operating cash flow fell 87.7% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+84.1%
$68.4M$125.9M

R&D investment increased 84.1% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-64.7%
-$69.0M-$113.6M

Net income declined 64.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-59.5%
-$98.8M-$157.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+43.2%
$17.5M$25.0M

Current liabilities surged 43.2% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+15.5%
$38.7M$44.7M

Liabilities increased 15.5% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
Overview We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming the liabilities associated with prior generations of TCEs.
+7 more — sign up free →
REMOVED
Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
Our (or the third parties with whom we work) actual or perceived failure to comply with current or future federal, state and foreign laws, regulations, contracts, self-regulatory schemes, industry standards and other obligations relating to privacy and security could lead to regulatory investigations or actions (which could include civil or criminal penalties), private litigation (including class claims) and mass arbitration demands, adverse publicity, disruptions of our business operations and other adverse business consequences.
Overview We are an innovative clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer.
Our proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).
Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, but overcome liabilities associated with prior generations of TCEs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →